Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Expenditures (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Capital Expenditures data on record, last reported at $2.1 million in Q2 2025.

  • For Q2 2025, Capital Expenditures fell 83.82% year-over-year to $2.1 million; the TTM value through May 2025 reached $13.4 million, down 27.07%, while the annual FY2025 figure was $13.4 million, 27.07% down from the prior year.
  • Capital Expenditures reached $2.1 million in Q2 2025 per LFCR's latest filing, down from $5.6 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $13.0 million in Q2 2024 and bottomed at -$7.4 million in Q2 2023.
  • Average Capital Expenditures over 5 years is $2.5 million, with a median of $3.4 million recorded in 2022.
  • The widest YoY moves for Capital Expenditures: up 977.39% in 2023, down 1584.68% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$6.8 million in 2021, then surged by 156.52% to $3.8 million in 2022, then increased by 18.87% to $4.6 million in 2023, then crashed by 50.2% to $2.3 million in 2024, then decreased by 7.95% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $2.1 million in Q2 2025, $5.6 million in Q1 2025, and $2.3 million in Q4 2024.